What amount sold does NextCure, Inc. report in Form D filings?

The latest linked filings report $129.9M sold across 3 identified offering(s). 0 unlinked amendment(s) are excluded; 0 offering(s) have no reported amount sold. This is not verified lifetime funding or money raised during a specific period.

When was NextCure, Inc.'s most recent SEC filing?

NextCure, Inc.'s most recent Form D filing was on 2025-12-09.

How many investors does NextCure, Inc. have?

The most recent Form D filing lists 12 investor(s).

NextCure, Inc.

NXTC

CIK: 0001661059·Biotechnology·BELTSVILLE, MD

Reported Sold

$129,932,873

Total Filings

Identified Offerings

Last Filed

Dec 9, 2025

Employees

—

Reported sold uses the latest linked filing for each identified offering; it is not verified lifetime funding. SPV filings are shown separately.

Offering filing timeline

Dec 9, 2025Form D — New notice

Reported sold: $21,500,000 · Target: $21,500,000

Rule 506(b)·12 investors

Nov 19, 2018Form D — New notice

Reported sold: $93,432,873 · Target: $93,432,873

Rule 506(b)·22 investors

Jan 11, 2016Form D — New notice

Reported sold: $15,000,000 · Target: $67,000,000

Rule 506(b)·7 investors

Fundraising Profile

Exemptions

Rule 506(b)

Investors in latest filing

Revenue Range

No Revenues

Reported commissions across identified offerings

Amendment Rate

Latest reported sold across 3 identified offerings

$129,932,873

Uses the latest linked filing for each offering. This is not a measure of money raised in the last year or verified lifetime funding.

Key People

David Kabakoff

Director

Appears on 2 filings

Michael Richman

Executive Officer, Director

Appears on 2 filings

Elaine V. Jones

Director

Appears on 2 filings

Stephen Webster

Director

Appears on 1 filing

Anne Borgman

Director

Appears on 1 filing

Ellen G. Feigal

Director

Appears on 1 filing

John G. Houston

Director

Appears on 1 filing

Steven P. Cobourn

Executive Officer

Appears on 1 filing

Filing History

Date	Type	Offering target	Reported sold	Investors
Dec 9, 2025	New	$21,500,000	$21,500,000	12
Nov 19, 2018	New	$93,432,873	$93,432,873	22
Jan 11, 2016	New	$67,000,000	$15,000,000	7

Filing History

Amendment insights

Loading amendment history…

Comparable issuers

Matched on reported industry and issuer type, then ranked by business location, offering target, and recency. These are filing comparables, not verified business competitors.

OS Therapies Inc

Biotechnology

Offering target: $12,282,478

Filed Oct 23, 2026